Mediphar Labs. has launched LOXIMED®tablet in November 2018 in the Lebanese market.

 

LOXIMED®is indicated for the treatment of respiratory tract infections, skin structure infections, intra-abdominal infections and plague.

We are proud to be introducing this medicament into the market, providing patients with a new and effective treatment option and further expand in antimicrobial therapy.

Loximed®is available in the below dosage

  • moxifloxacin 400 mg, pack of 7 tablets. 
Back to All News
We care about your questions and concerns. Please call the consumer healthcare service:
+961 4 540056 or by email: chs@medipharlabs.com